Adare Pharma Solutions is a world leader in organic-phase coacervation for pharmaceutical products.

Our proprietary taste masking platforms can improve product acceptability and patient adherence

Increasingly, format flexibility is becoming a requirement to address patient issues such as swallowing. The FDA also continues to push for pediatric-friendly formulations. Taste, smell, and mouth feel are the key product features to address when developing pediatric formulations. And Incremental formulation and clinical research costs require cost-effective solutions with flexibility in manufacturing scale. These drivers are why customers continue to come back to Adare Pharma Solutions for their taste-masking challenges.

Among various taste masking strategies, physical barrier is one of the most efficient technologies, and Adare offers industrially feasible physical barrier technologies, such as Microcaps®  and Optimµm®, for taste masking and dosage forms for pediatric populations.

Microencapsulation by coacervation:

As the world leader in coacervation, Adare’s Microcaps® technology is widely scene as the industry leading taste-masking solution with a wide variety of delivery formats.

  • Uniform coating of a solid particle or liquid droplet with a rigid semi-permeable polymer
  • Creates a physical barrier:
    • Effective taste masking
    • Customized release profile
    • Turn liquids into powders
    • Combine incompatible APIs
  • Final dosage forms:
    • Powder
    • Dry syrup
    • Orally disintegrating tablets
    • Parvulet® dosage form: food-like texture

Core In the manufacturing
vehicle
Deposition
of Gel-like
coating
Completed
Capsules

Proprietary Taste-Masking Process

Although spherical particles are shown (yellow), the Microcaps® coacervation process can also be used for varying non-isometric particle shapes.

Our Process Also Offers:

  • Small Particle Size – down to 150-200 µm
  • Highly efficient coating – usually 10-20%
  • Tunable and reproducible dissolution profile
  • Short processing time – one shift
  • Processing time not impacted by coating amount
  • High manufacturing capacity
  • Can manage different particle shapes

Adare’s Optimµm® technology provides innovative taste masking opportunities not seen before in oral pharmaceutical products

Optimµm® is developed and manufactured through Adare’s Precision Particle Fabrication™ technology, which produces uniform microspheres and microcapsules. Optimµm® is an elegant and robust solution with countless applications. You can learn more about how Optimµm® is manufactured using Precision Particle Fabrication™, here.

Optimµm® Multiparticulates are able to deliver:

  • Uniformity
  • Format Flexibility
  • Dose Flexibility
  • Taste Masking
  • Variable Release Kinetics
  • Single-step Microcapsules

 

The Broadest Variety of Taste-Masking Solutions in the Industry

Adare Pharma Solutions employs a variety of strategies for achieving successful taste-masking results for our customers, including:

API Taste Modifiers or Suppressants

  • Sweeteners
  • Flavors
  • Bitter receptor blocker or antagonists
  • Potentiators
  • Effervescents

 

API Solubility Modifier

  • pH Modifier
  • Gellation or Viscosity Enhancer
API Barrier

  • Molecular/Ionic Barrier via complexation [Ion exchange resins or cyclodextrins]
  • Physical barrier via coating or granulation, etc. [polymers or lipids or similar excipients]

 

API Modification

Modify solubility or taste using:

  • Salt
  • Polymorph
  • Cocrystal
  • Prodrug

 

Speak With An Expert

Profile Photo: Nathan Dormer

Nathan Dormer

Director, Drug Product Development

Nathan Dormer, Ph.D., is the Senior Director of Drug Product Development & Site Leader at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s facilities, supporting a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.

Contact Me